Equities research analysts expect that Elanco Animal Health (NYSE:ELAN) will report sales of $795.30 million for the current quarter, Zacks reports. Two analysts have provided estimates for Elanco Animal Health’s earnings, with estimates ranging from $794.40 million to $796.19 million. Elanco Animal Health reported sales of $799.30 million in the same quarter last year, which indicates a negative year over year growth rate of 0.5%. The business is expected to announce its next earnings results on Wednesday, February 5th.
On average, analysts expect that Elanco Animal Health will report full year sales of $3.08 billion for the current year, with estimates ranging from $3.07 billion to $3.08 billion. For the next financial year, analysts forecast that the firm will report sales of $3.12 billion, with estimates ranging from $3.10 billion to $3.14 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Elanco Animal Health.
Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 6th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.04. Elanco Animal Health had a return on equity of 7.79% and a net margin of 3.04%. The business had revenue of $771.30 million during the quarter, compared to analysts’ expectations of $765.85 million. During the same quarter in the previous year, the business earned $0.29 EPS. The company’s revenue for the quarter was up 1.3% on a year-over-year basis.
NYSE ELAN traded down $0.39 on Thursday, reaching $26.46. The company had a trading volume of 4,004,726 shares, compared to its average volume of 5,205,029. The firm has a market capitalization of $10.10 billion, a PE ratio of 22.42 and a beta of 0.71. Elanco Animal Health has a 1 year low of $25.25 and a 1 year high of $35.46. The firm has a 50-day moving average of $26.92 and a 200-day moving average of $29.44. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.12 and a quick ratio of 1.67.
In other Elanco Animal Health news, Director Deborah Turner Kochevar bought 1,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average cost of $27.95 per share, with a total value of $27,950.00. Also, Director John P. Bilbrey bought 3,766 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was acquired at an average cost of $26.58 per share, for a total transaction of $100,100.28. Following the completion of the transaction, the director now owns 2,783 shares in the company, valued at $73,972.14. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 4,994 shares of company stock worth $134,038. 0.04% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Winthrop Partners WNY LLC acquired a new position in shares of Elanco Animal Health in the 3rd quarter valued at approximately $25,000. Institutional & Family Asset Management LLC acquired a new position in shares of Elanco Animal Health in the 3rd quarter valued at approximately $28,000. San Francisco Sentry Investment Group CA raised its position in shares of Elanco Animal Health by 196.7% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,157 shares of the company’s stock valued at $31,000 after purchasing an additional 767 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Elanco Animal Health during the 2nd quarter valued at approximately $32,000. Finally, Toth Financial Advisory Corp acquired a new stake in shares of Elanco Animal Health during the 3rd quarter valued at approximately $33,000. 98.65% of the stock is currently owned by institutional investors.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Further Reading: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.